Latest news:

BioStock-article: Follicum approaches Phase II study with proDERM

BioStock published an article on 14 November 2019 about Follicum, which can be read in full below. Biotech company Follicum will conduct its upcoming Phase II study in hair loss together with the German CRO proDERM. The Charité Universitätsmedizin Berlin had previously been confirmed as a partner for the study, which is expected to start […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Hair growth

Our drug candidate FOL-005 has demonstrated increased hair growth on both healthy individuals and on patients with alopecia in two clinical phase II trials, which both demonstrated good safety and efficacy.

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




11 Nov 19
BIO Europe

Follicum will attend the BIO Europe conference in Hamburg 11-13 November 2019 More information will...